EWTX:NASDAQEdgewise Therapeutics, Inc. Analysis

Edgewise Therapeutics is trading at $32.77, just below its 20‑day SMA of $32.96 but comfortably above the 50‑day SMA of $32.27, indicating a modest bullish bias. The RSI sits near 49, suggesting neutral momentum, while the MACD histogram remains negative, hinting at short‑term bearish pressure. Volatility is elevated at roughly 68% over the past 30 days and beta exceeds 1.1, amplifying price swings. The stock sits above a support level near $30.12 and faces resistance around $39.96, with an implied upside of about 33% versus a downside of similar magnitude. Market sentiment is at “Extreme Greed” (Fear & Greed Index 90.2), reflecting strong speculative interest.
Fundamentally, the company has no revenue and reports negative earnings, yet it holds nearly $500 M in cash against minimal debt, resulting in a high price‑to‑book multiple (~7.1×). Analysts (12) maintain a “Buy” consensus with median price targets near $45.5, buoyed by recent news of promising Phase II trial data and increased R&D spending, which could unlock future value despite the current lack of commercial sales.